Ropes & Gray represented Pfizer Inc. in connection with its proposed acquisition of Medivation, Inc. a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Medivation common stock for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The closing of the tender offer is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Medivation common stock.
Ropes & Gray previously represented Pfizer on its agreement to acquire Hospira in 2015.
The Ropes & Gray team advising Pfizer included mergers & acquisitions partner Christopher Comeau, securities & public companies partner Paul Kinsella, tax partner David Saltzman, benefits partners Renata Ferrari and Jenny Rikoski, business & securities litigation partner Peter Welsh, government enforcement partner Alexandre Rene, real estate partner Peter Alpert, and securities & public companies associates Tara Fisher and Benjamin DiCamillo.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.